A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB.
| Autor: | Potter JL; Department of Respiratory Medicine, Barts Health NHS Trust, London, UK., Capstick T; Department of Medicines Management and Pharmacy Services, Leeds University Hospitals Trust, Leeds, UK., Ricketts WM; Department of Respiratory Medicine, The Whittington Hospital, London, UK., Whitehead N; Department of Respiratory Medicine, Queen Alexandra Hospital, Portsmouth, UK., Kon OM; Imperial College London, Chest and Allergy Clinic, London, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Thorax [Thorax] 2015 Mar; Vol. 70 (3), pp. 297-8. Date of Electronic Publication: 2014 Jun 13. |
| DOI: | 10.1136/thoraxjnl-2014-205278 |
| Abstrakt: | Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs currently available in the UK to treat TB. These recommendations provide a structure through which healthcare professionals can better manage the complex drug regimens required for the treatment of MDR-TB; minimising the risk of adverse incidents and helping to improve patients' tolerance, compliance and treatment completion. (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|